Welcome to our dedicated page for TBPMF news (Ticker: TBPMF), a resource for investors and traders seeking the latest updates and insights on TBPMF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TBPMF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TBPMF's position in the market.
Tetra Bio-Pharma has partnered with Dalton Pharma Services for the GMP manufacturing of its new anti-inflammatory drug candidate ARDS-003, derived from the active pharmaceutical ingredient HU-308. This collaboration aims to advance the drug through clinical trials in Canada and the USA, with significant progress reported in the manufacturing processes and compliance with regulatory standards. The production plan emphasizes the urgency of bringing this investigational drug to market as a potential treatment for cytokine release syndromes.
Tetra Bio-Pharma (OTCQB:TBPMF) and Mondias Natural Products have finalized an agreement to acquire Lumiera Health Innovation. The acquisition is set for submission at Mondias' shareholder meeting on September 14, 2020. The agreement includes the issuance of new shares for Lumiera's existing shares and the amalgamation of Mondias' subsidiary Laboratoire Holizen. A minimum of $1 million equity financing is required for completion. The deal is seen as beneficial for long-term shareholder value, offering access to Lumiera's intellectual property and product pipeline in chronic pain and inflammation.